Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.10% | 49.69% | 33.45% | 22.11% | 19.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.73% | 85.70% | 87.29% | 42.90% | 25.86% |
| Operating Income | -40.73% | -85.70% | -87.29% | -42.90% | -25.86% |
| Income Before Tax | -40.99% | -115.37% | -87.33% | -17.75% | -24.27% |
| Income Tax Expenses | 151.29% | 240.74% | -82.82% | 800.00% | 123.41% |
| Earnings from Continuing Operations | -41.33% | -116.11% | -86.01% | -17.87% | -26.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.33% | -116.11% | -86.01% | -17.87% | -26.73% |
| EBIT | -40.73% | -85.70% | -87.29% | -42.90% | -25.86% |
| EBITDA | -40.71% | -85.71% | -87.31% | -42.89% | -25.87% |
| EPS Basic | -23.20% | -112.56% | -66.55% | -5.29% | -13.02% |
| Normalized Basic EPS | -22.89% | -111.89% | -67.74% | -26.57% | -10.85% |
| EPS Diluted | -23.20% | -112.56% | -66.55% | -5.29% | -13.02% |
| Normalized Diluted EPS | -22.89% | -111.89% | -67.74% | -26.57% | -10.85% |
| Average Basic Shares Outstanding | 14.71% | 1.66% | 11.68% | 11.94% | 12.13% |
| Average Diluted Shares Outstanding | 14.71% | 1.66% | 11.68% | 11.94% | 12.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |